Ety Klinger
11Patents
7h-index
9Co-inventors
55Inventor score
Filing activity: Dec 4, 2002 → May 22, 2015
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7429374B2 | Process for the measurement of the potency of glatiramer acetate | Physics | 30 | Expired |
| US7923215B2 | Process for the measurement of the potency of glatiramer acetate | Physics | 28 | Active |
| US8232250B2 | Low frequency glatiramer acetate therapy | Human Necessities | 21 | Active |
| US8389228B2 | Process for the measurement of the potency of glatiramer acetate | Physics | 18 | Active |
| US8399413B2 | Low frequency glatiramer acetate therapy | Human Necessities | 17 | Active |
| US8969302B2 | Low frequency glatiramer acetate therapy | Human Necessities | 14 | Active |
| US9155776B2 | Low frequency glatiramer acetate therapy | Human Necessities | 10 | Active |
| US9402874B2 | Low frequency glatiramer acetate therapy | Human Necessities | 6 | Active |
| US7294687B2 | Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus | Performing Operations; Transporting | 2 | Expired |
| US8759314B2 | Methods for treating multiple sclerosis using antisense oligonucleotides | Chemistry; Metallurgy | 2 | Active |
| US8415314B2 | Methods for treating multiple sclerosis using antisense oligonucleotides | Chemistry; Metallurgy | 2 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.